Posted by Michael Wonder on 24 Jul 2019
Alnylam launches Onpattro (patisiran) for the treatment of polyneuropathy in hATTR amyloidosis, the first-ever RNAi therapeutic approved in Canada
23 July 2019 - Onpattro is the only treatment that demonstrated improvement, relative to baseline, in both polyneuropathy and quality of life measures in patients with hATTR amyloidosis.
Alnylam Pharmaceuticals today announced the Health Canada approval and immediate availability of Onpattro (patisiran) for the treatment of polyneuropathy in adult patients with hereditary transthyretin-mediated (hATTR) amyloidosis. Onpattro is the only treatment in Canada indicated for all stages of polyneuropathy associated with hATTR amyloidosis, a progressive, debilitating, chronic and often fatal disease.
Onpattro is based on Nobel Prize-winning science and is the first ever RNAi therapeutic to be approved in Canada.
